|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.82 HKD | +2.51% |
|
+14.06% | -20.08% |
| Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
| Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
April 14 (Reuters) - China's CanSino Biologics Inc said on Wednesday that no serious blood clot cases related to its COVID-19 vaccine had been reported so far.
The announcement comes amid multiple cases of people being diagnosed with a blood clot after receiving COVID-19 shots made by AstraZeneca and Johnson & Johnson. (Reporting by Shashwat Awasthi in Bengaluru; Editing by Shounak Dasgupta)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 1.07B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -17.69% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
CANSINO BIOLOGICS INC. 
